Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3050% below fair value
$2.56−0.16 (-5.88%)
Close on Nov 20, 2026Market cap $504.91MP/E –Yield –
Wave Life Sciences shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Wave Life Sciences's shares outstanding was 204M at Sep 30, 2026. For fiscal 2025 it was 169M, up 22.0% from the year before. Over ten years it grew 32.0% a year on average. The highest annual figure on record is 169M in fiscal 2025.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 169M | +22.0% |
| FY2024 | Dec 31, 2024 | 138M | +30.3% |
| FY2023 | Dec 31, 2023 | 106M | +34.5% |
| FY2022 | Dec 31, 2022 | 79M | +52.2% |
| FY2021 | Dec 31, 2021 | 52M | +32.1% |
| FY2020 | Dec 31, 2020 | 39M | +15.8% |
| FY2019 | Dec 31, 2019 | 34M | +16.9% |
| FY2018 | Dec 31, 2018 | 29M | +9.3% |
| FY2017 | Dec 31, 2017 | 27M | +16.3% |
| FY2016 | Dec 31, 2016 | 23M | +117.1% |
| FY2015 | Dec 31, 2015 | 11M | +168.5% |
| FY2014 | Dec 31, 2014 | 4M | +124.4% |
| FY2013 | Dec 31, 2013 | 2M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 204M | +21.7% |
| Q2 FY2026 | Jun 30, 2026 | 204M | +24.4% |
| Q1 FY2026 | Mar 31, 2026 | 200M | +23.1% |
| Q4 FY2025 | Dec 31, 2025 | 180M | +11.5% |
| Q3 FY2025 | Sep 30, 2025 | 168M | +26.5% |
| Q2 FY2025 | Jun 30, 2025 | 164M | +26.6% |
| Q1 FY2025 | Mar 31, 2025 | 163M | +25.8% |
| Q4 FY2024 | Dec 31, 2024 | 162M | +45.9% |
| Q3 FY2024 | Sep 30, 2024 | 133M | +23.9% |
| Q2 FY2024 | Jun 30, 2024 | 130M | +22.8% |
| Q1 FY2024 | Mar 31, 2024 | 129M | +26.7% |
| Q4 FY2023 | Dec 31, 2023 | 111M | +17.7% |
| Q3 FY2023 | Sep 30, 2023 | 107M | +13.9% |
| Q2 FY2023 | Jun 30, 2023 | 105M | +58.6% |
| Q1 FY2023 | Mar 31, 2023 | 102M | +68.6% |
| Q4 FY2022 | Dec 31, 2022 | 94M | +64.5% |
| Q3 FY2022 | Sep 30, 2022 | 94M | +85.2% |
| Q2 FY2022 | Jun 30, 2022 | 66M | +33.0% |
| Q1 FY2022 | Mar 31, 2022 | 61M | +23.2% |
| Q4 FY2021 | Dec 31, 2021 | 57M | +17.2% |
| Q3 FY2021 | Sep 30, 2021 | 51M | +32.2% |
| Q2 FY2021 | Jun 30, 2021 | 50M | +41.9% |
| Q1 FY2021 | Mar 31, 2021 | 49M | +42.5% |
| Q4 FY2020 | Dec 31, 2020 | 49M | +42.4% |
| Q3 FY2020 | Sep 30, 2020 | 38M | +11.9% |
| Q2 FY2020 | Jun 30, 2020 | 35M | +2.8% |
| Q1 FY2020 | Mar 31, 2020 | 34M | +5.7% |
| Q4 FY2019 | Dec 31, 2019 | 34M | +16.4% |
| Q3 FY2019 | Sep 30, 2019 | 34M | +16.9% |
| Q2 FY2019 | Jun 30, 2019 | 34M | +17.6% |
| Q1 FY2019 | Mar 31, 2019 | 33M | +16.8% |
| Q4 FY2018 | Dec 31, 2018 | 29M | +5.9% |
| Q3 FY2018 | Sep 30, 2018 | 29M | +5.7% |
| Q2 FY2018 | Jun 30, 2018 | 29M | +8.3% |
| Q1 FY2018 | Mar 31, 2018 | 28M | +18.6% |
| Q4 FY2017 | Dec 31, 2017 | 28M | +18.4% |
| Q3 FY2017 | Sep 30, 2017 | 28M | – |
| Q2 FY2017 | Jun 30, 2017 | 27M | – |
| Q1 FY2017 | Mar 31, 2017 | 24M | – |
| Q4 FY2016 | Dec 31, 2016 | 23M | – |
See a number that looks wrong?